AU728909B2 - Immunological method - Google Patents

Immunological method Download PDF

Info

Publication number
AU728909B2
AU728909B2 AU76631/98A AU7663198A AU728909B2 AU 728909 B2 AU728909 B2 AU 728909B2 AU 76631/98 A AU76631/98 A AU 76631/98A AU 7663198 A AU7663198 A AU 7663198A AU 728909 B2 AU728909 B2 AU 728909B2
Authority
AU
Australia
Prior art keywords
specific
cell
cells
antigen
subset
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU76631/98A
Other languages
English (en)
Other versions
AU7663198A (en
Inventor
Richard Andrew Kay
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Dundee
Original Assignee
University of Dundee
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Dundee filed Critical University of Dundee
Publication of AU7663198A publication Critical patent/AU7663198A/en
Application granted granted Critical
Publication of AU728909B2 publication Critical patent/AU728909B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047Cells of the immune system
    • G01N33/505Cells of the immune system involving T-cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • C07K14/7051T-cell receptor (TcR)-CD3 complex
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
AU76631/98A 1997-05-27 1998-05-27 Immunological method Ceased AU728909B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9710820 1997-05-27
GBGB9710820.3A GB9710820D0 (en) 1997-05-27 1997-05-27 Immunological method
PCT/GB1998/001382 WO1998054223A2 (en) 1997-05-27 1998-05-27 Immunological method

Publications (2)

Publication Number Publication Date
AU7663198A AU7663198A (en) 1998-12-30
AU728909B2 true AU728909B2 (en) 2001-01-18

Family

ID=10813057

Family Applications (1)

Application Number Title Priority Date Filing Date
AU76631/98A Ceased AU728909B2 (en) 1997-05-27 1998-05-27 Immunological method

Country Status (6)

Country Link
EP (1) EP1017724A2 (ja)
JP (1) JP2001517958A (ja)
AU (1) AU728909B2 (ja)
CA (1) CA2291004A1 (ja)
GB (1) GB9710820D0 (ja)
WO (1) WO1998054223A2 (ja)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1243327A1 (de) * 2001-03-19 2002-09-25 BioChip Technologies GmbH Oberfläche mit einem Muster aus Zellen und Verfahren zu deren Herstellung
GB0128153D0 (en) * 2001-11-23 2002-01-16 Bayer Ag Profiling of the immune gene repertoire
ES2478446T3 (es) 2003-06-27 2014-07-22 International Institute Of Cancer Immunology, Inc. Método de selección de pacientes candidatos para la vacuna contra WT1
EP3173480A3 (en) 2007-03-05 2017-08-16 International Institute of Cancer Immunology, Inc. Cancer antigen-specific t-cell receptor gene, peptide encoded by the gene, and use of them
US9803246B2 (en) 2011-06-28 2017-10-31 International Institute Of Cancer Immunology, Inc. Receptor gene for peptide cancer antigen-specific T cell

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2671356B1 (fr) * 1991-01-09 1993-04-30 Inst Nat Sante Rech Med Procede de description des repertoires d'anticorps (ab) et des recepteurs des cellules t (tcr) du systeme immunitaire d'un individu.
JPH07504399A (ja) * 1991-08-28 1995-05-18 ザ・ウィスター・インスティチュート T細胞リセプターに基づいた慢性間接リウマチの治療法
WO1994014067A1 (en) * 1992-12-14 1994-06-23 T Cell Sciences, Inc. Diagnosis and therapy of sarcoidosis
AU3878697A (en) * 1996-06-20 1998-02-02 Cornell Research Foundation Inc. Identification of abnormalities in the expression of t and cell antigen receptors as indicators of disease diagnosis, prognosis and therapeutic predictors

Also Published As

Publication number Publication date
CA2291004A1 (en) 1998-12-03
EP1017724A2 (en) 2000-07-12
GB9710820D0 (en) 1997-07-23
WO1998054223A2 (en) 1998-12-03
WO1998054223A3 (en) 1999-03-04
AU7663198A (en) 1998-12-30
JP2001517958A (ja) 2001-10-09

Similar Documents

Publication Publication Date Title
EP0463101B2 (en) Vaccination and methods against diseases resulting from pathogenic responses by specific t cell populations
Weyand New insights into the pathogenesis of rheumatoid arthritis
US5298396A (en) Method for identifying T cells disease involved in autoimmune disease
US20070238099A1 (en) Antigen Receptor Variable Region Typing
Norris et al. Oligoclonal expansion of intraepidermal T cells in psoriasis skin lesions
KR20060033899A (ko) T 세포 수용체 서열, 및 류마티스 관절염을 검출 및치료하는 방법
Müschen et al. Involvement of soluble CD95 in Churg-Strauss syndrome
EP0722738A2 (en) Vaccination and methods against diseases resulting from pathogenic responses by specific T cell populations
US7972848B2 (en) Isolation and identification of cross-reactive T cells
WO1991009623A1 (en) Diagnosis and treatment of diseases
US6464978B1 (en) Vaccination and methods against multiple sclerosis resulting from pathogenic responses by specific T cell populations
AU3418893A (en) Vaccination and methods against diseases resulting from pathogenic responses by specific t cell populations
AU728909B2 (en) Immunological method
WO2002089832A2 (en) Pharmaceutical compositions for preventing or treating th1 and th2 cell related diseases by modulating the th1/th2 ratio.
US5837246A (en) Vaccination and methods against diseases resulting from pathogenic responses by specific T cell populations
WO1993004695A1 (en) T cell receptor-based therapy for rheumatoid arthritis
Moesta et al. T cell receptor β chain gene usage in endemic pemphigus foliaceus (Fogo Selvagem)
AU648753C (en) Vaccination and methods against diseases resulting from pathogenic responses by specific T cell populations
Walters T cell repertoires in animal and huma glomerulonephritis
WO2004084822A2 (en) Methods for inducing immune tolerance
Klatzmann et al. Severe Perturbations of the Blood T Cell
AU6440999A (en) Composition for preventing or treating a T-cell mediated pathology

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)